TLL 018
Alternative Names: TLL-018Latest Information Update: 28 Jun 2025
At a glance
- Originator TLL Pharmaceutical
- Developer Hangzhou Highlightll Pharmaceutical; TLL Pharmaceutical
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Chronic urticaria; Rheumatoid arthritis
- Phase II Plaque psoriasis; Ulcerative colitis
- Phase I Atopic dermatitis
Most Recent Events
- 28 Jun 2025 No recent reports of development identified for phase-I development in Chronic-urticaria in China (PO, Tablet)
- 10 Mar 2025 Hangzhou Highlightll Pharmaceutical initiates enrollment in a phase-III Long-term Extension trials in Rheumatoid arthritis (Treatment-experienced) in China (PO) (NCT06887127)
- 24 Dec 2024 Phase-III clinical trials in Chronic-urticaria (Treatment-experienced) in China (PO, Tablet) (NCT06396026)